SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against GW Pharmaceuticals plc and Strongly Encourages Investors to Contact the Firm

0
39

Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by GW Pharmaceuticals plc (“GW Pharmaceuticals” or the “Company”) (NASDAQ: GWPH). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

“management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.”
Tweet this

If you purchased shares of GW Pharmaceuticals during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on whether the Company’s discovery of a material weakness in its internal control over financial reporting. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.”

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

NO COMMENTS